Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to its lead pipeline candidate, Seralutinib, and the PROSERA study results [1][4]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2]. - The PROSERA patient population was characterized by the company as well-suited to demonstrate a treatment effect [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].